Evidence map›Paper›PMID 40880013›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026

Multi-omics characterization of cachexia-related genes reveals prognostic signatures and immune landscape in breast cancer.

Siyu Wang, Hongxia Zhu, Wendi Zhan, Bo Hao, Zhuo Li, Taolan Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Siyu WangDepartment of Medical Oncology, Hengyang Medical School, The First Affiliated Hospital, University of South China, Hengyang, 421001, Hunan, China.
Hongxia ZhuDepartment of Pharmacy, Hengyang Medical School, The First Affiliated Hospital, University of South China, 69 Chuanshan Road, Hengyang, 421001, Hunan, China.
Wendi ZhanDepartment of Pharmacy, Hengyang Medical School, The First Affiliated Hospital, University of South China, 69 Chuanshan Road, Hengyang, 421001, Hunan, China.
Bo HaoDepartment of Pharmacy, Hengyang Medical School, The First Affiliated Hospital, University of South China, 69 Chuanshan Road, Hengyang, 421001, Hunan, China.
Zhuo Li *Department of Pharmacy, Hengyang Medical School, The First Affiliated Hospital, University of South China, 69 Chuanshan Road, Hengyang, 421001, Hunan, China.
Taolan Zhang *Department of Pharmacy, Hengyang Medical School, The First Affiliated Hospital, University of South China, 69 Chuanshan Road, Hengyang, 421001, Hunan, China. TaolZhan@usc.edu.cn.ORCID http://orcid.org/0009-0009-0236-9278

Funding

Science and technology innovation Program of Hengyang City grant number 202250045223the Clinical Research 4310 Program of the First Affiliated Hospital of the University of South China grant number 20224310NHYCG04the National Natural Science Foundation of China grant number 82473965 to TLZthe Natural Science Foundation of Hunan Province grant number 2023JJ50156 to TLZthe project of Hunan health high-level youth backbone talents grant number 20240304125 to ZTL
6 · The paper itself

Abstract

backgroundCancer cachexia is a multifactorial syndrome affecting cancer prognosis and immune microenvironment. However, the roles of cachexia-related genes (CRGs) in breast cancer remain unclear.

methodsWe performed differential expression analysis and weighted gene co-expression network analysis (WGCNA) on TCGA-BRCA data to identify key CRGs. A prognostic model was constructed using LASSO-Cox regression. Immune infiltration and treatment sensitivity were assessed, and single-cell RNA-seq analyses were conducted to explore gene function and cell-cell interactions.

resultsA total of 82 CRGs were identified, and an 11-gene prognostic model was constructed, showing high predictive accuracy across multiple cohorts. Based on this model, we created a new risk score (Cachexia-related Risk Score for Breast Cancer, CRSBC) to categorize patients into high and low-risk groups. Low-risk patients had a better prognosis and good immune infiltration with higher sensitivity to immunotherapy. Single-cell analysis revealed HCCS as a key gene enriched in epithelial cells (breast cancer cells) and involved in macrophages recruitment via the MIF signaling pathway.

conclusionsThis study reveals the prognostic and immunological significance of CRGs in breast cancer and highlights HCCS as a potential therapeutic target.

Indexed as

Breast NeoplasmsCachexiaBiomarkers, TumorFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMultiomicsPrognosisSingle-Cell AnalysisTumor MicroenvironmentBiomarkers, TumorIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMIF protein, humanBreast cancerCancer cachexiaTumor immune microenvironment

Identifiers

PMID40880013
PMCPMC12855450

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.